Novartis Pursuing Trileptal Pediatric Monotherapy Indication
This article was originally published in Pharmaceutical Approvals Monthly
Novartis is in discussions with FDA over the proper course to obtain a pediatric monotherapy indication for its antiepileptic Trileptal. FDA initially turned down the indication due to a lack of data on the most effective dose for use in children, review documents indicate.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class